23 October 2024
Treating opioid use disorder significantly lowers the very high rate (8 times the general population) of suicide among people with opioid dependence.
A Scottish study, led by Glasgow Caledonian University, supported by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol reports of over 45,000 patients receiving methadone or buprenorphine for opioid use disorder reported this important result in the scientific journal Addiction.
There were 575 suicides among the group of 46,453 people with opioid use disorder, accounting for 1.2% of the group. Although every member of the group received an OAT prescription at some point between 2011 and 2020, some of those suicides occurred during periods when people were not in receipt of an OAT prescription. The study assumed that every suicide that occurred more than 60 days after the person received an OAT prescription would have happened while the person was not on drug treatment for opioid dependence.
When researchers divided the 575 suicide deaths into those occurring while the person was on OAT versus those committed while the person was no longer on OAT, they found that the rate of suicide for people not on OAT was more than three times higher than the rate for people on OAT. [See figure.]
Lead author and researcher at Glasgow Caledonian University Rosalyn Fraser comments:
“People with opioid dependence in Scotland are at much higher risk of suicide than the general population. But there is strong evidence that suicide rates are lower among people receiving methadone or buprenorphine. OAT helps people access other support services, stabilises drug use, and provides opportunities to build therapeutic relationships and reduce isolation. It’s very important to get people with opioid dependence into drug treatment to reduce their suicide risk.”
Senior author and Glasgow Caledonian University Professor in Public Health Andrew McAuley added:
“In Scotland, trends in suicide in people who are opioid dependent declined during a period where overdose deaths more than doubled. Importantly, retention in opioid agonist treatment is a critical intervention both for suicide and opioid overdose prevention strategies.”
Matthew Hickman, Professor in Public Health and Epidemiology in Bristol Medical School: Population Health Sciences (PHS) and Head of Bristol’s HPRU, said:
“We do think the reduction in suicide when people are on Opioid Agonist Treatment (OAT) is due to combination of pharmacotherapy and psychological interventions delivered during OAT. However, we did not have detailed exposure information on the intensity or duration of psychological interventions. We note also that suicide rate in people who are dependent on opioids in Scotland is substantially higher than risk in the general population and higher than equivalent populations elsewhere – such as people in OAT in New South Wales. Therefore, the implication is whether additional self-harm and suicide prevention interventions should be added to psychological interventions delivered during OAT and whether it is possible to target these to people with opioid dependence who are greater risk of suicide.”
Further information
About HPRUs
By delivering high-quality collaborative research, the HPRUs support UKHSA in its objective to protect the health of the public, enabling it to prepare for and respond to major or emerging health protection incidents, as well as building an evidence base for health protection policy and practice.
The aims of the HPRUs are to:
- create an environment where world class health protection research, focused on the needs of the public, can thrive.
- focus on priority areas which will have the greatest impact on public health protection.
- provide high quality research evidence to inform decision-making by public health professionals, policy makers, those involved in operational delivery and service users.
- enable translation of advances in health protection research into benefits for patients, service users and the public.
- increase capacity and capability to conduct high quality, multi-disciplinary health protection research and facilitate knowledge exchange and expertise across universities and UKHSA.
- provide a flexible staff capacity in the event of a major health protection incident and retain a level of responsive research capacity to address emerging health protection research requirements.
- contribute to addressing health inequalities through an increasing focus on underserved communities including relevant interventions, improving health outcomes in the health and care sector and for broader economic gain.
Each HPRU is a centre of excellence in multi-disciplinary health protection research in a distinct priority area. The latest round of funding includes:
- £11 million to an HPRU focused on antimicrobial resistance, where infections become harder to treat, which is one of the biggest public health threats globally.
- The HPRU in Climate Change and Health Security to tackle the health threats from climate change including infectious disease risks, flooding and extreme heat.
- The HPRU in Emerging Zoonoses focuses on emerging diseases that originate in wildlife such as mpox, which pose a significant threat to human health.
- The HPRU in Emergency Preparedness and Response focused on strengthening preparedness for major public health emergencies including pandemics and terrorism.
Additional funding of £3 million is being made through two Health Protection Research Focus Awards on vaccines and immunisation and emergency preparedness and response.
Competitively funded by DHSC since 2014, the HPRUs have successfully supported the health response to major domestic and global emergencies including the Salisbury Novichok poisonings, West Africa Ebola outbreak, COVID-19, and the 2022 and 2024 mpox outbreaks.
Collectively, the HPRUs’ COVID-19 research had national and global impact; informing the Scientific Advisory Group for Emergencies (SAGE), the Scientific Pandemic Infections Group on Modelling (SPI-M), and guidance published by the National Institute for Health and Care Excellence (NICE) as well as the World Health Organisation.